α
AlphaScala
StocksSignalsNEWAlpha ScoreBrokers
Sign InGet Started
α
AlphaScala

Professional trading analysis with publicly tracked portfolios on TipRanks. Real trades, real data.

Markets

ForexStocksCryptoCommodities

Tools

Stock ResearchMarket SignalsAlpha ScoreHedge Funds 13FInsider BuysAgentic TradingAI Broker MatcherBroker ReviewsPortfoliosFree IndicatorsBlogLearn TradingTrading Q&A

Account

Sign InDashboardNewsletterContact UsAdvertise

Legal

AboutEditorial PolicyCorrectionsTerms of ServicePrivacy PolicyRisk Disclaimer

Risk Warning: AlphaScala provides educational content only and is not a financial advisor. Trading and investing involves substantial risk of loss and is not suitable for all investors. Past performance does not guarantee future results. You should consult a licensed financial advisor before making investment decisions. See our full risk disclaimer.

For AI AgentsAlphaScala is agent-ready —skill.md·llms.txt
© 2026 ROGA AI LIMITED · Registered in Gibraltar · Unit G02, Eurocity, Europort Avenue, Gibraltar GX11 1AAAlphaScala — Built with data, not hype.
All Stocks/Healthcare/ELVN

Enliven Therapeutics, Inc.

ELVN
HealthcareBiotechnology Website
Signal SnapshotMarket signals →
Alpha Score
Score pending
Alpha Score appears once the required price and fundamentals data has ingested.
Daily model
Insiders
No recent signal
No recent open-market insider buying or selling is in the current rollup.
Form 4
13F Holder
Point72
$23.17M reported position; latest action: new.
Steve Cohen
Latest Filing
No filing digest
Recent 10-K, 10-Q, and 8-K summaries will appear here when available.
SEC digest
Price ChartPowered by TradingView
Ask about ELVNAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Point72
Steve Cohen
1.50M$23.17MNEW
Citadel
Ken Griffin
1.44M$22.21MNEW
Blackstone955K$14.71MNEW
Marshall Wace372K$5.73MNEW
Explore all tracked funds →
About Enliven Therapeutics, Inc.

Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases. The primary focus of the company lies in advancing the field of precision medicine, which aims to tailor medical treatment to the individual characteristics of each patient, enhancing treatment efficacy and minimizing side effects. Enliven Therapeutics Inc. is actively engaged in researching and developing targeted therapies that address unmet medical needs across various therapeutic areas, particularly concentrating on genetic disorders and oncology. By leveraging cutting-edge technology platforms and innovative research methodologies, Enliven Therapeutics seeks to offer groundbreaking treatments that have a significant impact on patient care and outcomes. The company plays a vital role in the pharmaceutical and healthcare sectors, contributing to the rapid evolution of personalized healthcare solutions. In the financial market, Enliven Therapeutics represents an integral component of the biotechnology sector, often garnering interest from investors focused on emerging biotech innovations and their potential to transform traditional medical practices.

CEO
Mr. Richard A. Fair
Employees
60
Quick Facts
Exchange—
SectorHealthcare
IndustryBiotechnology
Market Cap—
Popular Stocks
AAPL
Apple Inc.
MSFT
Microsoft Corporation
NVDA
NVIDIA Corporation
AMZN
Amazon.com Inc.
GOOGL
Alphabet Inc. Class A
GOOG
Alphabet Inc. Class C
META
Meta Platforms Inc.
TSLA
Tesla Inc.
Key Dates

Earnings calendar coming soon. Subscribe to get notified when ELVN reports next.

Get earnings alerts →